SG11201704495VA - Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same - Google Patents
Compositions comprising 15-hepe and methods of treating or preventing fibrosis using sameInfo
- Publication number
- SG11201704495VA SG11201704495VA SG11201704495VA SG11201704495VA SG11201704495VA SG 11201704495V A SG11201704495V A SG 11201704495VA SG 11201704495V A SG11201704495V A SG 11201704495VA SG 11201704495V A SG11201704495V A SG 11201704495VA SG 11201704495V A SG11201704495V A SG 11201704495VA
- Authority
- SG
- Singapore
- Prior art keywords
- hepe
- compositions
- treating
- methods
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086535P | 2014-12-02 | 2014-12-02 | |
| PCT/US2015/063488 WO2016090030A1 (en) | 2014-12-02 | 2015-12-02 | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201704495VA true SG11201704495VA (en) | 2017-06-29 |
Family
ID=56092410
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201704495VA SG11201704495VA (en) | 2014-12-02 | 2015-12-02 | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same |
| SG10202010594WA SG10202010594WA (en) | 2014-12-02 | 2015-12-02 | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202010594WA SG10202010594WA (en) | 2014-12-02 | 2015-12-02 | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10363235B2 (ja) |
| EP (2) | EP3226873B1 (ja) |
| JP (2) | JP6986445B2 (ja) |
| KR (1) | KR20170102879A (ja) |
| CN (2) | CN107206008A (ja) |
| AU (2) | AU2015358512B2 (ja) |
| BR (1) | BR112017011685A2 (ja) |
| CA (1) | CA2968980A1 (ja) |
| ES (1) | ES2900593T3 (ja) |
| HK (1) | HK1245101A1 (ja) |
| IL (2) | IL252431B (ja) |
| MA (1) | MA41120A (ja) |
| MX (2) | MX2017007000A (ja) |
| PH (1) | PH12017501022A1 (ja) |
| RU (2) | RU2020115523A (ja) |
| SG (2) | SG11201704495VA (ja) |
| WO (1) | WO2016090030A1 (ja) |
| ZA (2) | ZA201704463B (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| CN109232278A (zh) | 2013-11-15 | 2019-01-18 | Ds生物制药有限公司 | 多不饱和羟基脂肪酸的药学上可接受的盐 |
| US20150196521A1 (en) * | 2014-01-10 | 2015-07-16 | Dignity Sciences Limited | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same |
| NZ744323A (en) * | 2015-12-18 | 2020-08-28 | Afimmune Ltd | Compositions comprising 15-hepe and methods of using the same |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6180671B1 (en) * | 1998-03-10 | 2001-01-30 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected |
| JP2000191525A (ja) | 1998-12-25 | 2000-07-11 | Nof Corp | 皮膚外用剤組成物 |
| WO2001049282A2 (en) * | 2000-01-06 | 2001-07-12 | Martek Biosciences Corporation | Therapeutic preparations of highly unsaturated fatty acids |
| ATE344226T1 (de) | 2000-02-16 | 2006-11-15 | Brigham & Womens Hospital | Aspirin-ausgelöste lipidmediatoren |
| JP2005179211A (ja) | 2003-12-17 | 2005-07-07 | Idemitsu Kosan Co Ltd | 皮膚外用剤組成物 |
| EP1711173A2 (en) | 2003-12-31 | 2006-10-18 | Igennus Limited | Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof |
| WO2005102309A2 (en) | 2004-04-26 | 2005-11-03 | Ltb4 Sweden Ab | In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration |
| CA2662987A1 (en) * | 2006-08-08 | 2008-02-21 | Tethys Bioscience, Inc. | Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof |
| US8042070B2 (en) * | 2007-10-23 | 2011-10-18 | International Business Machines Corporation | Methods and system for analysis and management of parametric yield |
| GB0802116D0 (en) * | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| WO2009154230A1 (ja) | 2008-06-17 | 2009-12-23 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防／改善・治療薬 |
| WO2010120880A1 (en) * | 2009-04-14 | 2010-10-21 | Vertex Pharmaceuticals Incorporated | Treatment of liver diseases with a caspase inhibitor |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| WO2012135032A2 (en) * | 2011-03-25 | 2012-10-04 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory particles |
| US20120264824A1 (en) * | 2011-04-15 | 2012-10-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| WO2013040316A1 (en) * | 2011-09-16 | 2013-03-21 | Galectin Therapeutics, Inc. | Galactomannan polysaccharide composition for the treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease |
| US8936803B2 (en) | 2011-10-19 | 2015-01-20 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| WO2013082265A1 (en) | 2011-11-29 | 2013-06-06 | Dignity Sciences Limited | Compositions comprising 20-carbon fatty acids and methods of making and using same |
| AU2012351939A1 (en) * | 2011-12-16 | 2014-07-10 | Tarix Pharmaceuticals Ltd. | Angiotensins for treatment of fibrosis |
| US20120264705A1 (en) | 2012-01-26 | 2012-10-18 | Dignity Sciences Limited | Antimicrobial compositions comprising 15-hetre and methods of use thereof |
| US20130267598A1 (en) | 2012-02-23 | 2013-10-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same |
| CN116173001A (zh) | 2012-05-10 | 2023-05-30 | 索卢泰克斯Na有限责任公司 | 含有天然专门促消退介质及其前体的具有抗炎活性的油 |
| GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| TWI689489B (zh) * | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| NZ744323A (en) | 2015-12-18 | 2020-08-28 | Afimmune Ltd | Compositions comprising 15-hepe and methods of using the same |
-
2015
- 2015-12-01 MA MA041120A patent/MA41120A/fr unknown
- 2015-12-02 RU RU2020115523A patent/RU2020115523A/ru unknown
- 2015-12-02 CN CN201580074543.0A patent/CN107206008A/zh active Pending
- 2015-12-02 SG SG11201704495VA patent/SG11201704495VA/en unknown
- 2015-12-02 JP JP2017527848A patent/JP6986445B2/ja active Active
- 2015-12-02 SG SG10202010594WA patent/SG10202010594WA/en unknown
- 2015-12-02 ES ES15865150T patent/ES2900593T3/es active Active
- 2015-12-02 BR BR112017011685-5A patent/BR112017011685A2/pt not_active Application Discontinuation
- 2015-12-02 AU AU2015358512A patent/AU2015358512B2/en not_active Ceased
- 2015-12-02 EP EP15865150.5A patent/EP3226873B1/en active Active
- 2015-12-02 CA CA2968980A patent/CA2968980A1/en not_active Abandoned
- 2015-12-02 WO PCT/US2015/063488 patent/WO2016090030A1/en active Application Filing
- 2015-12-02 EP EP21200516.9A patent/EP3988101A1/en not_active Withdrawn
- 2015-12-02 MX MX2017007000A patent/MX2017007000A/es unknown
- 2015-12-02 RU RU2017122758A patent/RU2721555C2/ru active
- 2015-12-02 KR KR1020177018195A patent/KR20170102879A/ko not_active Application Discontinuation
- 2015-12-02 CN CN202011279675.6A patent/CN112245419A/zh active Pending
-
2016
- 2016-03-07 US US15/062,636 patent/US10363235B2/en active Active
-
2017
- 2017-05-22 IL IL252431A patent/IL252431B/en unknown
- 2017-05-29 MX MX2021005080A patent/MX2021005080A/es unknown
- 2017-06-01 PH PH12017501022A patent/PH12017501022A1/en unknown
- 2017-06-30 ZA ZA2017/04463A patent/ZA201704463B/en unknown
-
2018
- 2018-04-06 HK HK18104557.7A patent/HK1245101A1/zh unknown
- 2018-06-29 ZA ZA2018/04380A patent/ZA201804380B/en unknown
-
2021
- 2021-05-18 AU AU2021203189A patent/AU2021203189A1/en not_active Abandoned
- 2021-11-10 IL IL287983A patent/IL287983A/en unknown
- 2021-11-29 JP JP2021192836A patent/JP2022031813A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1247238B (zh) | 改造的crispr-cas9組合物和使用方法 | |
| HRP20192145T1 (hr) | Pripravci nosača-antitijela i metode pripreme i uporabe istih | |
| ZA201701909B (en) | Trichoderma compositions and methods of use | |
| ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
| PL3349743T3 (pl) | Sposoby i kompozycje do hamowania oddziaływania dcn1-ubc12 | |
| HK1249515A1 (zh) | 預防和治療聽力損失的方法和組合物 | |
| ZA201607878B (en) | Compositions and methods of treating cardiac fibrosis with ifetroban | |
| SG11201702554QA (en) | Compositions and methods for the treatment of multiple sclerosis | |
| ZA201804380B (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same | |
| HK1252057A1 (zh) | 新穎的使用方法和組合物 | |
| HK1250345A1 (zh) | 包含15-氧代-epa或15-氧代-dgla的組合物及其製備和使用方法 | |
| HK1247136A1 (zh) | 包含15-hepe的組合物和其使用方法 | |
| HK1244692A1 (zh) | 治療纖維化的方法 | |
| IL256843B (en) | Cleaning products and methods of using them | |
| GB201511799D0 (en) | Composition and methods of treatment | |
| HK1243404A1 (zh) | 色酰胺組合物和使用方法 | |
| IL273850A (en) | Preparations and methods for the treatment of leprosy | |
| GB201621737D0 (en) | Compositions and methods of treatment | |
| GB201605127D0 (en) | Composition and methods of treatment | |
| IL261794A (en) | Preparations and methods for using them | |
| IL247645A0 (en) | Preparations of seleno-organic compounds and methods of using them | |
| EP3194446A4 (en) | Compositions and methods for treating fibrosis | |
| AU2015903210A0 (en) | Compositions and methods of treatment | |
| GB201521083D0 (en) | Compositions for treatment and methods thereof | |
| SG11201704282UA (en) | Compositions and methods for the treatment of multiple sclerosis |